Literature DB >> 9621105

Glycosphingolipid expression in pig aorta: identification of possible target antigens for human natural antibodies.

E C Hallberg1, J Holgersson, B E Samuelsson.   

Abstract

Total non-acid glycosphingolipids were isolated from the aortas of more than 80 pigs. The glycolipids were separated by HPLC, analysed by thin-layer chromatography, and tested for reactivity with monoclonal anti-blood group antibodies. The fractions were structurally characterized by NMR spectroscopy and mass spectrometry. Reactivity with both anti-blood group A and H antibodies was seen. The major glycosphingolipid constituents were globotri- and globotetraosylceramides and blood group H pentaglycosylceramides based on type 1 and type 2 core saccharide chains. Globopentaosylceramides, blood group H hexaglycosylceramides based on type 4 chain, and blood group A hexaglycosylceramides based on type 1 core chain were also present. Two structures, that may be important targets for human antibodies initiating hyperacute rejection following pig to human xenotransplantation, were present as minor constituents compared to the blood group components. These were Galalpha1,3neolactotetraosylceramide and a Galalpha1, 3Lexstructure. A Leb/Y hexaglycosylceramide was also present.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621105     DOI: 10.1093/glycob/8.7.637

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  2 in total

1.  Liquid chromatography "on-flow" 1H nuclear magnetic resonance on native glycosphingolipid mixtures together with gas chromatography/mass spectrometry on the released oligosaccharides for screening and characterisation of carbohydrate-based antigens from pig lungs.

Authors:  A E Bäcker; S Thorbert; O Rakotonirainy; E C Hallberg; A Olling; M Gustavsson; B E Samuelsson; B Soussi
Journal:  Glycoconj J       Date:  1999-01       Impact factor: 2.916

Review 2.  Tumor-Associated Glycans and Immune Surveillance.

Authors:  Behjatolah Monzavi-Karbassi; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Vaccines (Basel)       Date:  2013-06-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.